Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

10/22/2026, 5:30 AM • The Motley Fool

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

10/19/2026, 4:10 AM • The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has transitioned to a commercial biotech with its approved gene-editing therapy Casgevy for blood disorders. The company has several promising pipeline candidates including CTX310 for cholesterol/triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611 as an anticoagulant. While significant clinical and commercial progress could drive substantial stock gains by 2030, investors face considerable risks including potential clinical trial failures and uncertain profitability economics for one-time gene-editing treatments.

10/18/2026, 5:13 PM • The Motley Fool

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

10/18/2026, 6:50 AM • The Motley Fool

Meridian International Center Unveils Inaugural New Architects of American Influence Cohort

Meridian International Center announced the inaugural cohort of 25 leaders across business, technology, culture, sports, and state government recognized for shaping U.S. global influence. The group spans sectors including AI, space, medicine, energy, and finance, reflecting how American power is increasingly exercised beyond Washington through private sector innovation, international relationships, and cross-sector partnerships.

10/16/2026, 11:53 AM • GlobeNewswire

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Vertex Pharmaceuticals is diversifying beyond its core cystic fibrosis business through its $10 billion acquisition of Crinetics Pharmaceuticals. The company now has Palsonify (approved for acromegaly) and Atumelnant (in development for rare hormonal disorders) with estimated peak revenue potential exceeding $5 billion. Combined with other pipeline candidates like povetacicept and gene-editing medicine Casgevy, Vertex's hormone disorder franchise could become a significant growth driver over the medium term.

10/15/2026, 10:41 AM • The Motley Fool

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

10/13/2026, 8:17 AM • The Motley Fool

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

10/11/2026, 7:09 PM • The Motley Fool

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board

Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.

09/17/2026, 8:00 AM • GlobeNewswire

My Top 5 Favorite Stocks for an Uncertain Market

The article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.

09/16/2026, 7:10 AM • The Motley Fool

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

09/14/2026, 10:40 AM • The Motley Fool

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.

09/11/2026, 11:09 AM • The Motley Fool

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.

09/08/2026, 5:25 PM • The Motley Fool

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

09/04/2026, 2:30 PM • The Motley Fool